If we annualise the second half, that gives EPS of ~3.9c and EBITDA of ~$4.8m... and that's without the full effect of all the acquisitions.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025